Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00350870 · ClinicalTrials.gov registry record · Phase 1

CBT With Disulfiram and Contingency Management

A Phase 1 study of Cocaine Abuse, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
181
Enrollment target
1
Study location

NCT00350870 is a Phase 1 study of Cocaine Abuse that has completed, run by Yale University. The registered enrollment target is 181 participants, below the 899-participant average among 9 other Cocaine Abuse trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00350870, a Phase 1 study of Cocaine Abuse, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
181 participants
Enrollment target
1
Study location

Study Summary

This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG disulfiram
  • BEHAVIORAL Placebo plus Contingency Management
  • DRUG Disulfiram plus Contingency Management

Study Locations (1)

Connecticut

  • APT Foundation - New Haven

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 2005-04
Est. Completion 2010-12
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00350870

The ClinicalTrials.gov registry entry for NCT00350870 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 899-participant average among 9 other Cocaine Abuse trials with a reported enrollment target (80% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cocaine Abuse appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00350870 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00350870 about?

NCT00350870 is a clinical study titled "CBT With Disulfiram and Contingency Management". This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).

What is the current status of trial NCT00350870?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2005-04. Estimated completion is 2010-12.

What conditions does trial NCT00350870 study?

This clinical trial studies the following conditions: Cocaine Abuse.

What interventions are being tested in trial NCT00350870?

The interventions under investigation include: Placebo (DRUG), disulfiram (DRUG), Placebo plus Contingency Management (BEHAVIORAL), Disulfiram plus Contingency Management (DRUG).

Who is sponsoring clinical trial NCT00350870?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00350870 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.